Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease
- PMID: 18157654
- DOI: 10.1007/s12031-007-0012-9
Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease
Abstract
Misfolding and abnormal aggregation of the neuronal protein alpha-synuclein has been implicated in the pathogenesis of Parkinson's disease and related neurological disorders, such as dementia with Lewy bodies. alpha-synuclein is a conventional cytosolic protein and is thought to exert its pathogenic function exclusively in the neuronal cytoplasm in a cell-autonomous manner. However, the current model is being challenged by a series of new observations that demonstrate the presence of alpha-synuclein and its aggregated forms in the extracellular fluid both in vivo and in vitro. Extracellular alpha-synuclein appears to be delivered by unconventional exocytosis of intravesicular alpha-synuclein, although the exact mechanism has not been characterized. Compared to the cytosolic alpha-synuclein, intravesicular alpha-synuclein is prone to aggregation and the potential source of extracellular aggregates. A number of tissue culture studies suggest that exposure to extracellular alpha-synuclein aggregates induces microglial activation, release of pro-inflammatory cytokines from astrocytes, and neurotoxicity. Thus, exocytosis of alpha-synuclein may be an important mechanism for amplifying and spreading degenerative changes from a small group of cells to its surrounding tissues, and it potentially provides therapeutic targets for halting the progression of the disease.
Similar articles
-
Clearance and deposition of extracellular alpha-synuclein aggregates in microglia.Biochem Biophys Res Commun. 2008 Aug 1;372(3):423-8. doi: 10.1016/j.bbrc.2008.05.045. Epub 2008 May 19. Biochem Biophys Res Commun. 2008. PMID: 18492487
-
Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.J Parkinsons Dis. 2015;5(3):413-24. doi: 10.3233/JPD-150630. J Parkinsons Dis. 2015. PMID: 26406122 Free PMC article. Review.
-
Microglial exosomes facilitate α-synuclein transmission in Parkinson's disease.Brain. 2020 May 1;143(5):1476-1497. doi: 10.1093/brain/awaa090. Brain. 2020. PMID: 32355963 Free PMC article.
-
Potential Modes of Intercellular α-Synuclein Transmission.Int J Mol Sci. 2017 Feb 22;18(2):469. doi: 10.3390/ijms18020469. Int J Mol Sci. 2017. PMID: 28241427 Free PMC article. Review.
-
Extracellular α--synuclein-a novel and crucial factor in Lewy body diseases.Nat Rev Neurol. 2014 Feb;10(2):92-8. doi: 10.1038/nrneurol.2013.275. Epub 2014 Jan 28. Nat Rev Neurol. 2014. PMID: 24468877 Review.
Cited by
-
Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease.Expert Rev Neurother. 2010 Jun;10(6):925-42. doi: 10.1586/ern.10.54. Expert Rev Neurother. 2010. PMID: 20518609 Free PMC article. Review.
-
Inflammasomes: mechanism of action, role in disease, and therapeutics.Nat Med. 2015 Jul;21(7):677-87. doi: 10.1038/nm.3893. Epub 2015 Jun 29. Nat Med. 2015. PMID: 26121197 Free PMC article. Review.
-
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.J Neuroinflammation. 2015 May 14;12:93. doi: 10.1186/s12974-015-0320-x. J Neuroinflammation. 2015. PMID: 25966683 Free PMC article.
-
Role of exosomes in the pathogenesis of inflammation in Parkinson's disease.Neural Regen Res. 2022 Sep;17(9):1898-1906. doi: 10.4103/1673-5374.335143. Neural Regen Res. 2022. PMID: 35142665 Free PMC article. Review.
-
Extracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation.Biomolecules. 2022 Apr 30;12(5):655. doi: 10.3390/biom12050655. Biomolecules. 2022. PMID: 35625583 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical